The INNs and outs of antibody nonproprietary names
Open Access
- 6 October 2015
- journal article
- editorial
- Published by Taylor & Francis in mAbs
- Vol. 8 (1) , 1-9
Abstract
An important step in drug development is the assignment of an International Nonproprietary Name (INN) by the World Health Organization (WHO) that provides healthcare professionals with a unique and universally available designated name to identify each pharmaceutical substance. Monoclonal antibody INNs comprise a –mab suffix preceded by a substem indicating the antibody type, e.g., chimeric (-xi-), humanized (-zu-), or human (-u-). The WHO publishes INN definitions that specify how new monoclonal antibody therapeutics are categorized and adapts the definitions to new technologies. However, rapid progress in antibody technologies has blurred the boundaries between existing antibody categories and created a burgeoning array of new antibody formats. Thus, revising the INN system for antibodies is akin to aiming for a rapidly moving target. The WHO recently revised INN definitions for antibodies now to be based on amino acid sequence identity. These new definitions, however, are critically flawed as they are ambiguous and go against decades of scientific literature. A key concern is the imposition of an arbitrary threshold for identity against human germline antibody variable region sequences. This leads to inconsistent classification of somatically mutated human antibodies, humanized antibodies as well as antibodies derived from semi-synthetic/synthetic libraries and transgenic animals. Such sequence-based classification implies clear functional distinction between categories (e.g., immunogenicity). However, there is no scientific evidence to support this. Dialog between the WHO INN Expert Group and key stakeholders is needed to develop a new INN system for antibodies and to avoid confusion and miscommunication between researchers and clinicians prescribing antibodies.Keywords
This publication has 41 references indexed in Scilit:
- Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding GlycansPLOS Pathogens, 2013
- Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingScience, 2011
- Immunogenicity of protein therapeutics: The key causes, consequences and challengesSelf/Nonself, 2010
- Structural Basis for Antibody Discrimination between Two Hormones That Recognize the Parathyroid Hormone ReceptorJournal of Biological Chemistry, 2009
- The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity AntibodiesJournal of Molecular Biology, 2008
- Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloningJournal of Immunological Methods, 2008
- High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework ScaffoldJournal of Molecular Biology, 2004
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997
- Antibody-antigen Interactions: Contact Analysis and Binding Site TopographyJournal of Molecular Biology, 1996
- Canonical structures for the hypervariable regions of immunoglobulinsJournal of Molecular Biology, 1987